The HA-nimesulide conjugates improved the density of goblet cells and the recovery of average corneal epithelial thickness when compared with commercial products Optive Fusion® and Restasis® in a BAC-induced experimental dry eye rabbit model, and reduced the infiltration of CD11b-positive cells comparable to the immunomodulator Restasis®. The gene discussed is ITGAM; the disease is Keratoconjunctivitis sicca.